

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Cardiovascular disease	Not applicable	<p>Studies in mice suggest that <i>myo</i>-inositol trispyrophosphate (ITPP) could help treat heart failure. The hemoglobin of normal mice treated with intraperitoneal or oral ITTP had less oxygen binding affinity than that of untreated mice, which led to more oxygen release to tissues and better exercise capacity. In a mouse model of severe heart failure, intraperitoneal ITTP increased exercise capacity by up to 63% compared with that seen in untreated controls ($p=0.005$). An oral dose also showed efficacy. The next step is to submit an IND, and Phase I trials are expected to begin in 3Q09.</p> <p>SciBX 2(7); doi:10.1038/scibx.2009.274 Published online Feb. 19, 2009</p>	<p>Patent application filed; applications owned by NormOxys Inc.; available for licensing</p>	<p>Biolo, A. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 9, 2009; doi:10.1073/pnas.0812381106 Contact: Wilson S. Colucci, Boston University School of Medicine, Boston, Mass. e-mail: wilson.colucci@bmc.org Contact: Claude Nicolau, NormOxys Inc., Medford, Mass. e-mail: claude.nicolau@normoxys.com Contact: Jean-Marie Lehn, Louis Pasteur University, Strasbourg, France e-mail: lehn@isis.u-strasbg.fr</p>